A Pharmaceutical Entrepreneur Seeks to Revolutionize Most cancers Therapy and Save His Brother’s Life


Can this entrepreneur persuade his potential buyers that his enterprise actually can change the world?

Develop Your Enterprise,
Not Your Inbox

Keep knowledgeable and be part of our every day e-newsletter now!


2 min learn


Unicorn Hunters, the present that gives viewers the chance to take a position immediately into high-growth potential corporations, introduced Starton Therapeutics in its third installment.

Starton CEO Pedro Lichtinger describes the corporate as “growing an method to offer folks with most cancers longer, high-quality lives; eliminating or minimizing the horrible negative effects they expertise every single day by unlocking the complete potential of authorized medicine.”

Within the episode, Lichtinger speaks about one particular therapy the corporate develops to regulate a type of blood most cancers, including that this isn’t the one innovation within the pipeline. A diversified product portfolio lowers dangers in case regulators don’t approve one, or may additionally ship a robust increase to valuation if all succeed.

Most cancers has hit Lichtinger shut, together with his brother grappling with an advanced type of the illness. The entrepreneur is in a race, not solely in direction of an IPO, however in opposition to time. His dedication is seen all through the episode in addition to his willpower to persuade each potential investor to capitalize an organization that expects to vary the world and, additionally, his family.

The panel of knowledgeable buyers that Lichtinger faces within the Circle of Cash (from Steve Wozniak to former U.S. Treasurer Rosa Rios) could select to take a position at this stage or dig deeper into the product, the corporate or the manager crew earlier than capitalizing the corporate. On the web site unicornhunters.com, amongst different sources, extra info is accessible to each potential investor.

The Unicorn Hunters present offers buyers with clear entry to pick pre-IPO funding alternatives, like Starton Therapeutics, spotlighting corporations in search of to succeed in the coveted $1 billion valuation.

To seek out out what occurs subsequent, you possibly can watch Lichtinger’s pitch and the end result right here.



Supply hyperlink

Leave a Reply

Your email address will not be published. Required fields are marked *